[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Suzhou Sanegene Bio Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":87},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,62],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100617917","phase-1-a-study-of-sgb-7342-in-subjects-with-obesity-or-overweight-100617917",false,"NCT07324850","A Study of SGB-7342 in Subjects With Obesity or Overweight","A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-7342 in Subjects With Obesity or Overweight","Inclusion Criteria:\n\n* Body Mass Index (BMI) within the range of 26.0 to 35.0 kg\u002Fm²\n* Have a stable body weight within 3 months\n* Participants must agree to use adequate contraception from signing the informed consent until 6 months after completion of the follow-up visit.\n* Willing to comply with the protocol required visit schedule and visit requirements and provide written informed consent.\n\nExclusion Criteria:\n\n* A history of or a current surgical or medical condition that, in the opinion of the Investigator, may put the subject at significant risk (according to Investigator's judgment) or interfere with the subject's participation in the clinical study.\n* Use of GLP-1R agonists for any indication within 6 months prior to administering the investigational drug.\n* Use of non-GLP1R medications for weight loss within 3 months prior to administering the investigational drug.\n* Alanine aminotransferase (ALT), total bilirubin (TBIL), aspartate aminotransferase (AST)\\> 1.5 × ULN, and deemed clinically significant by the Investigators","ALL","18 Years","55 Years",{"count":20,"type":21},45,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The purpose of this study is to evaluate the safety and tolerability of subcutaneously administered SGB-7342 in adult subjects with obesity and overweight.",[27],"Obesity & Overweight","NOT_YET_RECRUITING","2026-01-07",{"date":31,"type":32},"2026-01-09","ACTUAL",{"date":34,"type":21},"2026-01-12",{"date":36,"type":21},"2027-04-14",{"name":38,"class":39},"Suzhou Sanegene Bio Inc.","INDUSTRY",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":4},"100592584","phase-1-a-study-of-sgb-3383-in-healthy-subjects-100592584","NCT06995326","A Study of SGB-3383 in Healthy Subjects","A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-3383 in Healthy Volunteers","Inclusion Criteria:\n\n* Weight ≥ 45.0 kg (female) or ≥ 50.0 kg (male), and Body Mass Index (BMI) within the range of 18.0 to 28.0 kg\u002Fm², inclusive\n* Physical examination, vital signs, 12-lead electrocardiogram, and laboratory tests be normal or slightly abnormal but not clinically significant according to investigator's judgement.\n* Participants must agree to use adequate contraception from signing the informed consent until 3 months after completion of the follow-up visit.\n* Willing to comply with the protocol required visit schedule and visit requirements and provide written informed consent.\n\nExclusion Criteria:\n\n* A history of or a current surgical or medical condition that, in the opinion of the Investigator, may put the subject at significant risk (according to Investigator's judgment) or interfere with the subject's participation in the clinical study.\n* History of meningococcal infection, or subjects from occupations or living environment at risk of Neisseria meningitidis exposure.\n* Positive result of hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), human immunodeficiency virus (HIV) antibody, or syphilis at screening.\n* Alanine aminotransferase (ALT), total bilirubin (TBIL), aspartate aminotransferase (AST)\\> 1.5 × ULN, and deemed clinically significant by the Investigators\n* QTcF values \\> 450 ms for male, and \\> 470 ms for female",true,{"count":49,"type":21},37,[24],"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of SGB-3383 in healthy subjects. The study will be designed as a single ascending dose (SAD) phase, utilizing a double-blind, placebo-controlled approach.",[53],"Healthy Volunteers","2025-05-28",{"date":56,"type":32},"2025-06-03",{"date":58,"type":21},"2025-06",{"date":60,"type":21},"2027-01",{"name":38,"class":39},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},"100576518","phase-2-a-study-of-sgb-9768-in-patients-with-complement-mediated-kidney-diseases-100576518","NCT06786338","A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases","A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of SGB-9768 in Patients with Primary IgA Nephropathy, C3 Glomerulopathy, and Immune Complex-mediated Membranoproliferative Glomerulonephritis.","Inclusion Criteria:\n\n* Aged ≥18 years\n* Weight ≥40 kg, with a body mass index (BMI) between 15 and 35 kg\u002Fm²\n* Biopsy-confirmed diagnosis of primary IgA nephropathy, C3 glomerulopathy or IC-MPGN, accompanied by C3 deposition in the glomeruli.\n* Urine protein-to-creatinine ratio (UPCR) ≥0.75 g\u002Fg\n* Estimated glomerular filtration rate (eGFR) (calculated using the CKD-EPI formula) must be ≥30 mL\u002Fmin\u002F1.73 m².\n* Must be on a stable maximum tolerated doses of ACE inhibitors (ACEI) or angiotensin receptor blockers (ARB) for at least 12 weeks\n* Participants of childbearing potential must use highly effective contraception during the study and for at least 12 weeks following the end of the study or last dose of study drug\n\nExclusion Criteria:\n\n* Kidney biopsy indicates more than 50% tubular atrophy or interstitial fibrosis.\n* Kidney biopsy shows more than 50% formation of glomerular crescents, or clinical signs suggestive of rapidly progressive glomerulonephritis.\n* IgA nephropathy, C3 glomerulopathy, or IC-MPGN secondary to other diseases\n* Presence of other systemic diseases or kidney diseases that may cause proteinuria\n* Received immunosuppressants or other immunomodulators within 90 days prior to the first administration of the investigational drug\n* Received B-cell targeted biologics or other biologics within 180 days prior to the first administration of the investigational drug\n* Used SGLT2 inhibitors or endothelin receptor antagonists, unless have been stably used for 12 weeks or more\n* Significant comorbidities\n* History of any malignant tumors of any organ system within the past 5 years\n* History of severe trauma or major surgery within 12 weeks prior to screening, or plans to undergo surgery during the study.\n* History of immunodeficiency diseases, congenital asplenia or splenectomy.\n* History of recurrent invasive infections, active systemic bacterial, viral, or fungal infections\n* Positive test results for HBV, HCV, HIV\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels \\> 2.5 times the upper limit of normal (ULN)",{"count":70,"type":21},38,[72],"PHASE2","This study looks at how well and safely SGB-9768 works for patients with certain kidney diseases: primary IgA nephropathy, C3 glomerulopathy, and immune complex-related membranoproliferative glomerulonephritis. It's a phase 2 trial done at several locations where both patients and doctors know what treatment is being given.",[75,76,77],"IgA Nephropathy (IgAN)","C3 Glomerulopathy","IC-MPGN","2025-01-20",{"date":80,"type":32},"2025-01-22",{"date":82,"type":21},"2025-04-01",{"date":84,"type":21},"2026-10-01",{"name":38,"class":39},11,""]